Journal
ANNALS OF ONCOLOGY
Volume 28, Issue -, Pages 13-15Publisher
OXFORD UNIV PRESS
DOI: 10.1093/annonc/mdx446
Keywords
ovarian cancer; platinum-resistant; relapse; heterogeneity; ctDNA
Categories
Funding
- National Health and Medical Research Council (NHMRC) [APP1092856]
- NHMRC [GNT1124309]
- Victorian Cancer Agency [ECSG15012]
- Peter MacCallum Cancer Centre Foundation
- U.S. Army Medical Research and Materiel Command [DAMD17-01-1-0729]
- Cancer Council Victoria
- Queensland Cancer Fund
- Cancer Council New South Wales
- Cancer Council South Australia
- Cancer Foundation of Western Australia
- Cancer Council Tasmania
- National Health and Medical Research Council of Australia (NHMRC) [628779]
- Ovarian Cancer Australia
- Spanish Ovarian Cancer Research Group (GEICO)
- European Society for Medical Oncology (ESMO)
Ask authors/readers for more resources
Most women diagnosed with high-grade serous ovarian cancer (HGSC) develop recurrent disease and chemotherapy resistance, despite initially responding to treatment. The genomic characteristics of HGSC samples collected at initial surgery have been extensively studied. However, due to challenges of sample collection following treatment, much less is known about the molecular features of recurrent disease. Our recent studies have identified mechanisms of acquired resistance and biomarkers in recurrent HGSCs that could lead to improved treatment approaches.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
